Segment Information (Tables)

6 Months Ended

Jun. 30, 2015

Segment Information

Schedule of consolidated financial information by segment

	Three months ended June 30,		Six months ended June 30,
(in millions)	2015	2014	2015	2014
HUMIRA	$ 3,537	$ 3,288	$ 6,648	$ 5,925
IMBRUVICA	107	—	107	—
VIEKIRA	385	—	616	—
Creon	159	110	286	217
Synagis	46	74	381	428
Lupron	198	186	390	375
Synthroid	187	166	373	323
Kaletra	167	216	347	411
AndroGel	170	218	323	472
Sevoflurane	118	154	244	296
Duodopa	55	56	108	108
Dyslipidemia products	38	65	81	161
All other	308	393	611	773
Total net revenues	$ 5,475	$ 4,926	$ 10,515	$ 9,489